Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has been awarded a contract from the National Institutes of Child Health and Human Development (NICHD) to provide clinical trial management services for a study to be conducted by the Division of Epidemiology, Statistics and Prevention Research (DESPR).
C-tasc to manage clinical trial data for National institutes of child health and human development
Division of Epidemiology, Statistics and Prevention Research Study Will Create Standards for Fetal Growth and Size for Gestational Age
Baltimore – (October 27, 2008) – Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has been awarded a federal Indefinite Delivery Indefinite Quantity (IDIQ) contract with a first task order totaling $1.7 million from the National Institutes of Child Health and Human Development (NICHD) to provide clinical trial management services for a study to be conducted by the Division of Epidemiology, Statistics and Prevention Research (DESPR).
Throughout the course of the study, C-TASC will use its StudyCTMSTM study management software solution to provide Data Coordinating Center (DCC) services, including a fully operational, state-of-the-art data management system, management of biospecimen and radiology data shipment and inventory, statistical expertise and programming and logistical support.
StudyCTMSTM is C-TASC’s proprietary Web-based data management solution that enables investigators to easily develop and manage clinical studies and deliver the accumulated data and metadata (labels, value labels, etc.) in an easy-to-read and FDA-acceptable format.
This study is the first in a series of projects C-TASC will complete for NICHD and DESPR. Entitled the “U.S. National Standard for Normal Fetal Growth and Size for Gestational Age,” this observational study will collect and analyze data from 3,000 healthy pregnant women over the next five years. The goals of the study are to establish a national standard for normal fetal growth and size for gestational age, create an individualized standard for optimal fetal growth and improve the accuracy of fetal weight estimation. Work on the study began in late September 2008 and is expected to finish in March of 2012.
“By employing our StudyCTMSTM software, C-TASC will be able to collect, analyze and report data easily and effectively for many of the clinical trials being conducted by DESPR,” said Bruce Thompson, president of C-TASC. “This first project gives C-TASC the opportunity to assist obstetricians in monitoring pregnancies and make a contribution to medicine that will benefit the health of infants across the United States.”
About C-TASC
Based in Baltimore, Clinical Trials & Surveys Corporation (C-TASC) is a clinical trials solutions company that supports best practices to run safe and effective clinical trials, clinical cohort studies, case/control studies, clinical registries and laboratory studies. Founded in 1989, C-TASC provides clients with complete research management including medical and statistical study design, project management, performance monitoring and data quality control and analysis as well as support for study publication and presentations. C-TASC’s professional services group has a successful research history in cancer, cardiovascular disease, AIDS, pulmonary disease, Cystic Fibrosis, pharmaco-epidemiology and bio-repository services and coordination. For more information about C-TASC’s projects, products and services, please visit www.c-tasc.com <http://www.c-tasc.com/> .
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.